Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of BIIB093 (Cirara) in Patients With Brain Contusion
NCT03954041Phase 2Terminated
- Sponsor
- Remedy Pharmaceuticals
- Start
- Oct 2019
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of glibenclamide in cerebral contusion (3 arms), sponsored by Remedy Pharmaceuticals. Primary endpoint: Change From Baseline in Mean Total Contusion Volume (Hematoma Plus Perihematomal Edema) at 96 Hours. Started Oct 2019; status: terminated.
02
Drugs
glibenclamide
03
Conditions
cerebral contusion
Beyond the preview
Go deeper on NCT03954041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03954041.